Pappas Capital, a Research Triangle Park, NC-based investor in next-generation life science and technology companies, announced that Nick Pappas has joined the firm as a Managing Partner of Pappas Ventures, the firm’s life science venture business.
In his role, Pappas will oversee Pappas Ventures and lead fundraising and investment efforts for its current and future venture funds. Previously, he served as a Managing Partner and Head of Investments at Philips Ventures, where he led a global investment program that was recognized as a leader in corporate venture capital. Pappas has over two decades of investing, banking and management experience with early-stage healthcare and technology companies. Prior to Philips, he spent seven years as a Partner and venture investor with MassVentures. Previously, Pappas was a senior technology investment banker with Oppenheimer & Co., SVB Alliant, and Canaccord Genuity, both in Silicon Valley and Boston. He received a BS in Business Administration from the University of Richmondand an MBA from the MIT Sloan School of Management.
Led by Art Pappas, CEO and Managing Partner, Pappas Capital is a global venture capital and commercial development firm investing in next-generation life science, agriculture, and technology companies. The firm has raised more than $800 million and has guided the launch or development of more than 100 companies through its Pappas Ventures business unit, its Specialized Fund Management unit, and its Translational Medicine initiative. Twenty-five FDA approved products have come from Pappas Capital portfolio companies.